ATYR Stock Risk & Deep Value Analysis
aTyr Pharma Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ATYR Stock
We analyzed aTyr Pharma Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ATYR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ATYR Risk Analysis & Red Flags
What Could Go Wrong
The FDA feedback on efzofitimod for pulmonary sarcoidosis could be negative or require extensive additional trials, leading to a significant cash burn that necessitates heavy dilution, potentially causing the stock to drop by 50% or more before any other pipeline assets mature.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
High
Red Flags
- ⚠
Mixed Phase 3 clinical trial results for efzofitimod in pulmonary sarcoidosis increase regulatory uncertainty.
- ⚠
Significant dependence on future capital raises to fund expensive Phase 3 trials and commercialization.
- ⚠
Lack of current revenue generation for a clinical-stage biotech.
- ⚠
Unreported or delayed FDA feedback on a critical lead candidate after Q1 2026 expectation.
Upcoming Risk Events
- 📅
Negative or unclear FDA feedback on efzofitimod for pulmonary sarcoidosis
- 📅
Phase 3 trial failures or delays for efzofitimod (dermatomyositis)
- 📅
Significant share dilution via future capital raises
- 📅
Worsening cash burn beyond current estimates
When to Reconsider
- 🚪
Exit if efzofitimod fails to receive positive FDA feedback for either sarcoidosis or dermatomyositis.
- 🚪
Sell if total cash on hand drops below $40M without a clear, non-dilutive funding plan.
- 🚪
Exit if any significant adverse events are reported in ongoing clinical trials.
Unlock ATYR Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does aTyr Pharma Inc (ATYR) Do?
Market Cap
$77.55M
Sector
Healthcare
Industry
Biotechnology
Employees
56
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Visit aTyr Pharma Inc WebsiteInvestment Thesis
aTyr Pharma is a high-risk, high-reward biotech offering 10x potential from its differentiated tRNA synthetase platform. The lead asset, efzofitimod, despite mixed Phase 3 data in pulmonary sarcoidosis, holds promise in rare inflammatory diseases like dermatomyositis, backed by Orphan Drug Designation. A substantial cash position relative to its market cap, combined with analyst price targets significantly above current levels, suggests the market is pricing in substantial risk, creating an opportunity for a significant re-rating upon positive clinical and regulatory milestones.
Is ATYR Stock Undervalued?
Unlock the full AI analysis for ATYR
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ATYR Price Targets & Strategy
12-Month Target
$8.50
Bull Case
$15.00
Bear Case
$0.50
Valuation Basis
Based on a re-rating to a market capitalization of $850M-$1.5B (implying 10x-18x current market cap) upon positive clinical milestones and regulatory clarity for efzofitimod in dermatomyositis and potential resolution in sarcoidosis, consistent with early commercial-stage rare disease biotechs. Current analyst median target is $25.67.
Entry Strategy
Dollar-cost average between $0.70-$1.00, observing for positive news flow regarding FDA feedback or clinical trial updates. Current price is near recent lows, representing a potential speculative entry point.
Exit Strategy
Take initial profits at $5.00-$8.00 as significant re-rating occurs; stop-loss at $0.55 if clinical setbacks or significant dilution materializes without progress.
Portfolio Allocation
5% for aggressive risk tolerance (given the high-risk, high-reward profile of a clinical-stage biotech).
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ATYR Financially Healthy?
Valuation
P/E Ratio
-8.20
Forward P/E
-1.08
PEG Ratio
-0.64
Profitability
Operating Margin
-14076.32%
Net Margin
-13549.47%
Return on Equity
-99.62%
Revenue Growth
-19.15%
EPS
$-0.80
Balance Sheet
Current Ratio
5.30
Quick Ratio
5.25
Debt/Equity
0.01
Cash & Equivalents
$79.00M
Cash Flow
Operating Cash Flow
-$62.00M
Free Cash Flow
-$62.00M
Other
Beta (Volatility)
0.67
Does ATYR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
2 Identified
The moat's durability relies heavily on successful clinical development and regulatory approvals, which would convert proprietary science into market exclusivity. If the clinical trials fail, the IP's value diminishes significantly.
Moat Erosion Risks
- •Clinical trial failures or significant delays for lead candidates.
- •Emergence of superior or more effective therapies from competitors.
- •Regulatory challenges or negative feedback from health authorities.
ATYR Competitive Moat Analysis
Sign up to see competitive advantages
ATYR Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. Limited broad retail investor discussion due to clinical-stage nature; likely focused among biotech specialists.
Institutional Sentiment
Neutral-to-Positive. Analyst consensus is 'Hold' with a high median price target, suggesting belief in long-term potential. Some institutional investors (e.g., ADAR1 Capital) have increased stakes.
Insider Activity (Form 4)
No specific Form 4 filings reported in the last 90 days indicating significant insider buying or selling.
Options Flow
Normal options activity; no unusual put/call ratio shifts or large block trades observed in the provided data.
Earnings Intelligence
Next Earnings
2026-05-06
Surprise Probability
Medium
Historical Earnings Pattern
Biotech stocks at this stage typically experience significant volatility around clinical news and funding announcements, rather than quarterly earnings which often just confirm cash burn.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (no specific peer listed in research; generally, other clinical-stage biotechs focused on rare inflammatory diseases)
Market Share Trend
Not applicable as the company is clinical-stage with no marketed products.
Valuation vs Peers
Difficult to compare directly due to clinical stage and lack of revenue. Current market cap is below cash, suggesting a negative valuation for the pipeline, implying it's significantly undervalued if a drug reaches market, or highly risky.
Competitive Advantages
- •Differentiated mechanism of action (tRNA synthetase biology)
- •Orphan Drug Designation provides potential market exclusivity and regulatory benefits
- •Targeting high-value, unmet medical needs in rare diseases
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ATYR Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report on 2026-05-06
- •FDA feedback on efzofitimod for pulmonary sarcoidosis (expected Q1 2026, now overdue/imminent)
- •Updates on ongoing Phase 3 trials for efzofitimod (dermatomyositis)
Medium-Term (6-18 months)
- •Potential initiation or advancement of additional efzofitimod trials in new indications
- •Strategic partnerships for commercialization or further development
- •Clinical data readouts from preclinical assets (ATYR0101, ATYR0750)
Long-Term (18+ months)
- •Regulatory approval and commercial launch of efzofitimod in rare inflammatory diseases
- •Expansion of tRNA synthetase therapy pipeline
- •Achieving market leadership in specific niche rare disease markets
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ATYR?
- ✓
Positive FDA clarity or approval pathway for efzofitimod in any indication.
- ✓
Better-than-expected progress in Phase 3 dermatomyositis trials.
- ✓
Announcements of strategic partnerships or non-dilutive funding.
Bull Case Analysis
See what could go right with Premium
Competing with ATYR
See how aTyr Pharma Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
aTyr Pharma Inc ATYR | $77.5M | 7.0 | -8.2 | — | -13549.5% | -19.1% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How aTyr Pharma Inc Makes Money
aTyr Pharma is a clinical-stage biopharmaceutical company that discovers and develops novel medicines for patients with rare diseases. The company identifies and develops tRNA synthetase-based therapeutics, focusing on targets that play a critical role in immune response and inflammatory pathways. Their business model is to advance these drug candidates through preclinical and clinical development phases, aiming for regulatory approval and eventual commercialization or out-licensing to generate revenue. Currently, the company does not have marketed products and operates by investing in R&D, funded primarily through equity financing.
Read Full Business Model BreakdownFAQ
What is the DVR Score for aTyr Pharma Inc (ATYR)?
As of April 29, 2026, aTyr Pharma Inc has a DVR Score of 7.0 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of aTyr Pharma Inc?
aTyr Pharma Inc's market capitalization is approximately $77.5M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does aTyr Pharma Inc use?
ATYR is the ticker symbol for aTyr Pharma Inc. The company trades on the NCM.
What is the risk level for ATYR stock?
Our analysis rates aTyr Pharma Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ATYR?
aTyr Pharma Inc currently has a price-to-earnings (P/E) ratio of -8.2. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is aTyr Pharma Inc's revenue growing?
aTyr Pharma Inc has reported revenue growth of -19.1%. Revenue has been declining, which warrants closer examination.
Is ATYR stock profitable?
aTyr Pharma Inc has a profit margin of -13549.5%. The company is currently unprofitable.
How often is the ATYR DVR analysis updated?
Our AI-powered analysis of aTyr Pharma Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 29, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ATYR (aTyr Pharma Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.